Rebecca Araujo

DocwireNews

A research team from Stockholm, Sweden, evaluated whether serum-free light chains (FLC) could detect treatment response or disease progression in multiple myeloma (MM) earlier than standard methods.The standard monitoring methods in MM are myeloma-protein measurements using serum and urine protein electrophoresis (sPEP/uPEP), according to the authors. However, serum FLC analysis, which is a complementary method used in <a href="https://www.docwirenews.com/docwire-pick/significant-variability-in-myeloma-risk-factor-testing-across-the-u-s/">diagnostics</a> and follow-up, has a shorter half-life compared with these traditional methods, or two to six hours versus up to 21 days, respectively.&ldquo;Involved FLC (iFLC) analysis could, in a temporal fashion, be of higher value for earlier treatment evaluation and, thus enabling a potentially better clinical decision making,&rdquo; explained the authors.For this study, the researchers enrolled 450 patients with MM who were assessed via iFLC, sPEP, and/or uPEP after first-, second-, and third-line therapy. Assessments were conducted according to International Myeloma Working Group guidelines, or after every fourth week for iFLC and sPEP and every fourth to twelfth week for uPEP. Primary outcomes were time to response and progression.The median time to partial response or better across all cohorts was detectable significantly earlier for patients monitored with iFLC compared with sPEP, or 1.94 months versus 5.39 months, respectively. In the first-line cohort, median time to response was detectable at 2.2 months for iFLC compared with 5.6 months for sPEP and 19.2 months for uPEP (P&lt;0.001). Earlier detection was found for iFLC in both first- and second-line groups, although the difference was not statistically significant among the third-line cohort. There was also no significant difference in time to disease progression between iFLC or sPEP.In conclusion, the authors wrote, iFLC &ldquo;predicted [median] responses at least three&thinsp;months before sPEP, regardless of the line of the treatment. The early detection of response might benefit the patients through a dose reduction and/or limit the number of drugs used in combination, due to eventual side effects.&rdquo;Findings from this study were published in <a href="https://www.tandfonline.com/doi/full/10.1080/10428194.2021.1907370">Leukemia &amp; Lymphoma</a>.

MarkAlain Déry, DO

The Significant Danger Measles Pose for Unvaccinated Children

Infectious Disease

Andrew Moreno

Antithrombotic Care in Hemophilia: A Summary of Multi-Organizational Clinical Practice Guidance

Hemophilia

James Tumlin, MD

Joel M. Topf, MD, FACP

Proteinuria Remission With Sparsentan in FSGS

NKF Spring Clinical Meetings 2025

Latest News

Free Light Chains Allow Earlier Detection of MM Treatment Response

Oncology

A research team from Stockholm, Sweden, evaluated whether serum-free light chains (FLC) could detect treatment response or disease progression in multiple myeloma (MM) earlier ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe